A screen of microbial-derived products using a 3D model of the human airway epithelium (bronchospheres) revealed flagellin (FLG) as a potential regulator of mucociliary structure and function. Flagellin, a TLR5-agonist, is the key protein component of bacterial flagella expressed by a number of organisms including Pseudomonas aeruginosa. Considering that mucus plugs in the airways of many cystic fibrosis (CF) patients would be reasonably expected to contain FLG, the epithelium is likely to be chronically exposed to this bacterial protein.
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The company is based in the UK with offices at the Sussex Innovation Centre.
- Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by RocheOctober 7, 2020 - 7:02 am
- Enterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002August 17, 2020 - 9:00 am
- Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical OfficerFebruary 10, 2020 - 9:00 am
- Enterprise Therapeutics publishes paper on novel therapeutic approach for treatment of all cystic fibrosis patientsJanuary 8, 2020 - 10:16 am
Follow Us On Twitter
Just a week to go until the premier of 'The Magic Line' virtual campaign video, raising awareness and donations to speed breakthroughs and cures for the 10% of the #CysticFibrosis community without targeted therapies: https://rb.gy/cbhaiw